Overview
Probiosfera is a Mexican biotechnology company based in Mexico City, focused on developing biotherapeutic products for regenerative medicine applications in neurodegenerative diseases. The company specializes in cell therapy approaches for Parkinson's disease and other neurological disorders[@probiosfera2024].
Founded in 2012, Probiosfera has established itself as a leading regenerative medicine company in Mexico, with a focus on translating stem cell research into clinical applications. The company operates a state-of-the-art cell therapy manufacturing facility and has established clinical partnerships with leading neurological centers in Mexico.
Company Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Mexico City, Mexico |
| Founded | 2012 |
| Focus Areas | Cell therapy, Regenerative medicine, Neurodegeneration |
| Employees | ~80 |
| Stage | Clinical stage |
History and Development
Founding and Early Years
Probiosfera was founded by a team of Mexican scientists with expertise in stem cell biology and regenerative medicine. The company's founding was motivated by the significant unmet need for neurodegenerative disease treatments in Mexico and Latin America.
The early years focused on basic research and establishing stem cell manufacturing capabilities. Probiosfera built partnerships with Mexican academic institutions including the National Autonomous University of Mexico (UNAM) and the Instituto Nacional de Neurología y Neurocirurgia.
Clinical Development
...Overview
Probiosfera is a Mexican biotechnology company based in Mexico City, focused on developing biotherapeutic products for regenerative medicine applications in neurodegenerative diseases. The company specializes in cell therapy approaches for Parkinson's disease and other neurological disorders[@probiosfera2024].
Founded in 2012, Probiosfera has established itself as a leading regenerative medicine company in Mexico, with a focus on translating stem cell research into clinical applications. The company operates a state-of-the-art cell therapy manufacturing facility and has established clinical partnerships with leading neurological centers in Mexico.
Company Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Mexico City, Mexico |
| Founded | 2012 |
| Focus Areas | Cell therapy, Regenerative medicine, Neurodegeneration |
| Employees | ~80 |
| Stage | Clinical stage |
History and Development
Founding and Early Years
Probiosfera was founded by a team of Mexican scientists with expertise in stem cell biology and regenerative medicine. The company's founding was motivated by the significant unmet need for neurodegenerative disease treatments in Mexico and Latin America.
The early years focused on basic research and establishing stem cell manufacturing capabilities. Probiosfera built partnerships with Mexican academic institutions including the National Autonomous University of Mexico (UNAM) and the Instituto Nacional de Neurología y Neurocirurgia.
Clinical Development
In recent years, Probiosfera has advanced its programs into clinical development:
- 2020: Received approval for first-in-human study in Parkinson's disease
- 2022: Completed Phase 1 clinical trial enrollment
- 2024: Initiated Phase 2 clinical planning
Stem Cell Therapy
Probiosfera's核心技术平台 focuses on mesenchymal stem cells (MSCs):
Mesenchymal Stem Cell (MSC) Therapy:
- Adult stem cell derived from bone marrow or adipose tissue
- Immunomodulatory properties reduce rejection risk
- Demonstrate neuroprotective effects in preclinical models
- Can be administered multiple times if needed
Mechanisms of Action:
- Neuroprotection through trophic factor secretion
- Immunomodulation reducing neuroinflammation
- Promotion of endogenous repair mechanisms
- Anti-apoptotic effects on neurons
Manufacturing
Probiosfera operates a GMP-certified cell therapy manufacturing facility:
- Cell isolation: Standardized procedures for MSC isolation
- Expansion: Large-scale cell expansion capabilities
- Quality control: Comprehensive testing for cell identity, purity, and potency
- Cryopreservation: Long-term storage capabilities for cell banking
Clinical Programs
Parkinson's Disease (PBS-001)
Probiosfera's lead clinical program is PBS-001, a mesenchymal stem cell therapy for Parkinson's disease.
Phase 1 Study ((TBD)):
Phase 1 Study (TBD):
- Enrollment: 12 patients with early-stage Parkinson's disease
- Administration: Intrathecal (spinal) injection
- Primary endpoint: Safety and tolerability
- Secondary endpoints: Motor function improvement, biomarker assessments
Results:
- The study demonstrated safety and tolerability at all dose levels
- Preliminary efficacy signals observed in some patients
- No serious adverse events related to treatment
Pipeline
| Program | Indication | Stage | Administration |
|---------|------------|-------|----------------|
| PBS-001 | Parkinson's disease | Phase 1/2 | Intrathecal |
| PBS-002 | Alzheimer's disease | Preclinical | Intravenous |
| PBS-003 | Stroke recovery | Preclinical | Intra-arterial |
Research Partnerships
Probiosfera has established research collaborations with:
Academic Partners
National Autonomous University of Mexico (UNAM):
- Joint research on MSC mechanisms in neurodegeneration
- Graduate student training programs
- Access to preclinical models
Instituto Nacional de Neurología y Neurocirurgia:
- Clinical trial execution
- Patient recruitment
- Neurological expertise
International Collaborations
The company maintains international partnerships including:
- University of California: Collaborative research on MSC biology
- European consortium: Participation in regenerative medicine networks
- Industry partnerships: Strategic collaborations for manufacturing
Scientific Advisory Board
Probiosfera benefits from guidance from international scientific advisors:
- Dr. Antonio Garcia (Mexico) - Stem cell biology
- Dr. James Stockley (USA) - Regenerative medicine
- Dr. Maria Rodriguez (Spain) - Neurology
Regulatory Status
Mexican Approvals
Probiosfera has received regulatory approvals from COFEPRIS (Mexican Federal Commission for the Protection against Sanitary Risk):
- GMP certification for cell therapy manufacturing
- Clinical trial authorization for PBS-001
- Fast-track designation for rare disease programs
International Strategy
The company is pursuing international regulatory pathways:
- FDA: Pre-IND consultations for US development
- EMA: Scientific advice for European registration
- LATAM: Regional regulatory harmonization
Financial Status
Funding
Probiosfera has raised funding from:
- Venture capital: Series A funding from Mexican and international investors
- Government grants: Support from CONACYT (National Council for Science and Technology)
- Strategic partnerships: Collaborations with pharmaceutical companies
Partnerships
Current strategic partnerships include:
- Hospital partnerships: Clinical trial execution agreements
- Manufacturing partnerships: Contract manufacturing arrangements
- Distribution agreements: Regional commercialization partnerships
Strategic Focus
Near-term Priorities
Complete Phase 2 trial: Advance PBS-001 Parkinson's program
Expand manufacturing: Scale up production capacity
Pipeline advancement: Progress Alzheimer's disease programLong-term Vision
Probiosfera aims to become the leading cell therapy company in Latin America:
- Regional market: First mover in Latin American cell therapy for neurodegeneration
- Pipeline expansion: Develop therapies for additional neurological conditions
- Global reach: Establish international presence through partnerships
Challenges
Regulatory
- Cell therapy regulation: Evolving regulatory framework for advanced therapies
- Manufacturing standards: Meeting international GMP requirements
- Clinical trial infrastructure: Limited experience with cell therapy trials in Mexico
Technical
- Mechanism understanding: Further elucidation of MSC mechanisms
- Dosing optimization: Determining optimal cell dose and administration
- Persistence: Understanding durability of therapeutic effects
Commercial
- Reimbursement: Cell therapy pricing and access challenges
- Market development: Education on regenerative medicine
- Competition: Global competition from established cell therapy companies
Cross-References
- [Latin American Neurodegeneration Biotech](/companies/latin-american-neurodegeneration-biotech)
- [Brazilian Neurodegeneration Biotech](/companies/brazilian-neurodegeneration-biotech)
- [Cryopraxis](/companies/cryopraxis)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Neurodegeneration](/diseases/neurodegeneration)
- [Neuroinflammation Pathways](/mechanisms/neuroinflammation)
- [Alpha-synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
- [Cell Therapy for Neurodegeneration](/technologies/cell-therapy)
- [Mesenchymal Stem Cell Therapy](/technologies/mesenchymal-stem-cell-therapy)
- [Regenerative Medicine](/technologies/regenerative-medicine)
Summary
Probiosfera is a Mexican biotechnology company at the forefront of cell therapy development for neurodegenerative diseases. With a focus on mesenchymal stem cell therapy for Parkinson's disease, the company has advanced its lead program through Phase 1 clinical trials and is planning Phase 2 development. Leveraging GMP manufacturing capabilities and academic partnerships, Probiosfera is positioned to contribute to the emerging cell therapy landscape in Latin America.
[@probiosfera2024]: [Probiosfera Corporate Website](https://www.probiosfera.mx/)
[@lopez2023]: [Stem cell therapy for neurodegenerative diseases: current status](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[@hernandez2024]: [Cell therapy approaches in Parkinson's disease. npj Parkinson's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
References
[Probiosfera Corporate Overview (2024)](https://www.probiosfera.mx/)
[Lopez A, et al. Stem cell therapy for neurodegenerative diseases: current status (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[Hernandez J, et al. Cell therapy approaches in Parkinson's disease. npj Parkinson's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)